Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring

Por Mueck, Wolfgang, Schwers, Stephan, Stampfuss, Jan
Publicado em 2013

Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

Por Mueck, Wolfgang, Kubitza, Dagmar, Becka, Michael
Publicado em 2013

Proposal for defining the relevance of drug accumulation derived from single dose study data for modified release dosage forms

Por Scheerans, Christian, Heinig, Roland, Mueck, Wolfgang
Publicado no Biopharm Drug Dispos (2015)

Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen

Por Kubitza, Dagmar, Becka, Michael, Mueck, Wolfgang, Zuehlsdorf, Michael
Publicado em 2007

Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls

Por Scheerans, Christian, Blunck, Martin, Mueck, Wolfgang, Frey, Reiner
Publicado em 2011

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

Por Mueck, Wolfgang, Stampfuss, Jan, Kubitza, Dagmar, Becka, Michael
Publicado em 2013

Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)

Por Frey, Reiner, Mueck, Wolfgang, Becka, Michael, Kraetzschmar, Joern, Wensing, Georg
Publicado em 2011

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment

Por Frey, Reiner, Becker, Corina, Unger, Sigrun, Schmidt, Anja, Wensing, Georg, Mueck, Wolfgang
Publicado em 2013

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment

Por Frey, Reiner, Becker, Corina, Unger, Sigrun, Schmidt, Anja, Wensing, Georg, Mueck, Wolfgang
Publicado em 2013

Absorption behavior of riociguat: bioavailability, food effects, and dose-proportionality

Por Becker, Corina, Frey, Reiner, Hesse, Christiane, Unger, Sigrun, Reber, Michael, Mueck, Wolfgang
Publicado em 2013

Effects of omeprazole and AlOH/MgOH on riociguat absorption

Por Becker, Corina, Frey, Reiner, Unger, Sigrun, Artmeier-Brandt, Ulrike, Weimann, Gerrit, Mueck, Wolfgang
Publicado em 2013

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor

Por Kubitza, Dagmar, Roth, Angelika, Becka, Michael, Alatrach, Abir, Halabi, Atef, Hinrichsen, Holger, Mueck, Wolfgang
Publicado em 2013

Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes

Por Xu, Xu Steven, Moore, Kenneth, Burton, Paul, Stuyckens, Kim, Mueck, Wolfgang, Rossenu, Stefaan, Plotnikov, Alexei, Gibson, Michael, Vermeulen, An
Publicado em 2012

Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation

Por Burghaus, Rolf, Coboeken, Katrin, Gaub, Thomas, Kuepfer, Lars, Sensse, Anke, Siegmund, Hans-Ulrich, Weiss, Wolfgang, Mueck, Wolfgang, Lippert, Joerg
Publicado em 2011

Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat

Por Becker, Corina, Frey, Reiner, Unger, Sigrun, Thomas, Dirk, Reber, Michael, Weimann, Gerrit, Dietrich, Hartmut, Arens, Erich R, Mueck, Wolfgang
Publicado em 2013

Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects

Por Zhao, Xia, Sun, Peihong, Zhou, Ying, Liu, Yuwang, Zhang, Huilin, Mueck, Wolfgang, Kubitza, Dagmar, Bauer, Richard J, Zhang, Hong, Cui, Yimin
Publicado em 2009

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

Por Kubitza, Dagmar, Becka, Michael, Mueck, Wolfgang, Halabi, Atef, Maatouk, Haidar, Klause, Norbert, Lufft, Volkmar, Wand, Dominic D, Philipp, Thomas, Bruck, Heike
Publicado em 2010

Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban—an oral, direct Factor Xa inhibitor

Por Burghaus, Rolf, Coboeken, Katrin, Gaub, Thomas, Niederalt, Christoph, Sensse, Anke, Siegmund, Hans-Ulrich, Weiss, Wolfgang, Mueck, Wolfgang, Tanigawa, Takahiko, Lippert, Jörg
Publicado no Front Physiol (2014)

Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease

Por Ghofrani, Hossein A., Staehler, Gerd, Grünig, Ekkehard, Halank, Michael, Mitrovic, Veselin, Unger, Sigrun, Mueck, Wolfgang, Frey, Reiner, Grimminger, Friedrich, Schermuly, Ralph T., Behr, Juergen
Publicado no Pulm Circ (2015)